VIROMETIX Trademark

Trademark Overview


On Monday, February 25, 2019, a trademark application was filed for VIROMETIX with the United States Patent and Trademark Office. The USPTO has given the VIROMETIX trademark a serial number of 79257237. The federal status of this trademark filing is ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE as of Monday, July 13, 2020. This trademark is owned by Virometix AG. The VIROMETIX trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Scientific and technological services, namely, scientific and technological research, analysis, and testing for the prevention and treatment of diseases, in particular for infectious, respiratory, oncological, and chronic diseases, as well as scientific research and design services for the prevention and treatment of diseases, in particular infectious, respiratory, oncological, and chronic diseases; industrial analysis and industrial research services, namely, industrial research and analysis for the prevention and treatment of diseases, in particular infectious, respiratory, oncological and chronic diseases; providing information and data on the subject of scientific and technological research and development for the prevention and treatment of diseases, in particular infectious, respiratory, oncological and chronic diseases; scientific and technological services, namely, scientific research, analysis, and testing in the field of development of vaccines, immunotherapeutic, immunologic...
virometix

General Information


Serial Number79257237
Word MarkVIROMETIX
Filing DateMonday, February 25, 2019
Status602 - ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE
Status DateMonday, July 13, 2020
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements


Goods and ServicesScientific and technological services, namely, scientific and technological research, analysis, and testing for the prevention and treatment of diseases, in particular for infectious, respiratory, oncological, and chronic diseases, as well as scientific research and design services for the prevention and treatment of diseases, in particular infectious, respiratory, oncological, and chronic diseases; industrial analysis and industrial research services, namely, industrial research and analysis for the prevention and treatment of diseases, in particular infectious, respiratory, oncological and chronic diseases; providing information and data on the subject of scientific and technological research and development for the prevention and treatment of diseases, in particular infectious, respiratory, oncological and chronic diseases; scientific and technological services, namely, scientific research, analysis, and testing in the field of development of vaccines, immunotherapeutic, immunological, pharmaceutical and diagnostic products, especially vaccines, immunotherapeutic and pharmaceutical and synthetic products like viruses, mimetic antigens and immunotherapeutic and synthetic products as well as nano-medicinal products, in particular for the prevention and treatment of infectious, respiratory, oncological and chronic diseases, as well as scientific and technological services, namely, scientific research, analysis, and testing in the field of discovering, development and formulation of medicinal products, product design and chemical synthesis, especially for vaccines, immunotherapeutic and pharmaceutical and synthetic products like viruses, mimetic antigens and immunotherapeutic and synthetic products as well as nano-medicinal products; scientific and technological services, namely, scientific research, analysis, and testing in the field of development of vaccines, immunotherapeutic, immunological, pharmaceutical and diagnostic products for the transfer of genetic material and for gene delivery, especially vaccines, immunotherapeutic and pharmaceutical and synthetic products like viruses, mimetic antigens and immunotherapeutic and synthetic products for the transfer of genetic material and for gene delivery, in particular for the prevention and treatment of infectious, respiratory, oncological and chronic diseases

Classification Information


International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateThursday, May 9, 2019
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameVirometix AG
Party Type10 - Original Applicant
Legal Entity Type25 - NOT AVAILABLE
AddressCH

Trademark Events


Event DateEvent Description
Saturday, July 31, 2021FINAL DECISION TRANSACTION PROCESSED BY IB
Tuesday, July 13, 2021FINAL DISPOSITION NOTICE SENT TO IB
Tuesday, July 13, 2021FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Saturday, October 17, 2020NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Wednesday, September 30, 2020NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Wednesday, September 30, 2020NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Monday, July 13, 2020ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
Monday, July 13, 2020ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Monday, December 30, 2019NOTIFICATION OF FINAL REFUSAL EMAILED
Monday, December 30, 2019FINAL REFUSAL E-MAILED
Monday, December 30, 2019FINAL REFUSAL WRITTEN
Friday, December 6, 2019TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, December 5, 2019CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, December 5, 2019TEAS RESPONSE TO OFFICE ACTION RECEIVED
Saturday, June 22, 2019REFUSAL PROCESSED BY IB
Thursday, June 6, 2019NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Thursday, June 6, 2019REFUSAL PROCESSED BY MPU
Wednesday, May 15, 2019NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Tuesday, May 14, 2019NON-FINAL ACTION WRITTEN
Tuesday, May 14, 2019APPLICATION FILING RECEIPT MAILED
Thursday, May 9, 2019ASSIGNED TO EXAMINER
Thursday, May 9, 2019NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Wednesday, May 8, 2019LIMITATION FROM ORIGINAL APPLICATION ENTERED
Thursday, April 25, 2019SN ASSIGNED FOR SECT 66A APPL FROM IB